Logo image of SNDX

SYNDAX PHARMACEUTICALS INC (SNDX) Stock Fundamental Analysis

NASDAQ:SNDX - Nasdaq - US87164F1057 - Common Stock - Currency: USD

10.08  -0.73 (-6.75%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SNDX. SNDX was compared to 561 industry peers in the Biotechnology industry. SNDX may be in some trouble as it scores bad on both profitability and health. SNDX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SNDX had negative earnings in the past year.
In the past year SNDX has reported a negative cash flow from operations.
SNDX had negative earnings in 4 of the past 5 years.
In the past 5 years SNDX reported 4 times negative operating cash flow.
SNDX Yearly Net Income VS EBIT VS OCF VS FCFSNDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

SNDX's Return On Assets of -51.69% is in line compared to the rest of the industry. SNDX outperforms 45.10% of its industry peers.
SNDX's Return On Equity of -154.01% is on the low side compared to the rest of the industry. SNDX is outperformed by 64.35% of its industry peers.
Industry RankSector Rank
ROA -51.69%
ROE -154.01%
ROIC N/A
ROA(3y)-36.06%
ROA(5y)-25.66%
ROE(3y)-60.12%
ROE(5y)-40.97%
ROIC(3y)N/A
ROIC(5y)N/A
SNDX Yearly ROA, ROE, ROICSNDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

With a decent Gross Margin value of 52.27%, SNDX is doing good in the industry, outperforming 76.65% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for SNDX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 52.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNDX Yearly Profit, Operating, Gross MarginsSNDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

SNDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
SNDX has more shares outstanding than it did 1 year ago.
SNDX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SNDX is higher compared to a year ago.
SNDX Yearly Shares OutstandingSNDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SNDX Yearly Total Debt VS Total AssetsSNDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

SNDX has an Altman-Z score of -2.39. This is a bad value and indicates that SNDX is not financially healthy and even has some risk of bankruptcy.
SNDX has a Altman-Z score of -2.39. This is comparable to the rest of the industry: SNDX outperforms 51.69% of its industry peers.
A Debt/Equity ratio of 1.54 is on the high side and indicates that SNDX has dependencies on debt financing.
The Debt to Equity ratio of SNDX (1.54) is worse than 81.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.54
Debt/FCF N/A
Altman-Z -2.39
ROIC/WACCN/A
WACC9.78%
SNDX Yearly LT Debt VS Equity VS FCFSNDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

SNDX has a Current Ratio of 5.80. This indicates that SNDX is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 5.80, SNDX is doing good in the industry, outperforming 61.85% of the companies in the same industry.
A Quick Ratio of 5.75 indicates that SNDX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 5.75, SNDX is in the better half of the industry, outperforming 62.39% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.8
Quick Ratio 5.75
SNDX Yearly Current Assets VS Current LiabilitesSNDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

SNDX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.88%.
Measured over the past years, SNDX shows a very strong growth in Revenue. The Revenue has been growing by 73.64% on average per year.
EPS 1Y (TTM)-19.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.29%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-44.66%
Revenue growth 5Y73.64%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 15.95% on average over the next years. This is quite good.
The Revenue is expected to grow by 46.04% on average over the next years. This is a very strong growth
EPS Next Y-0.52%
EPS Next 2Y13.05%
EPS Next 3Y16.07%
EPS Next 5Y15.95%
Revenue Next Year4.29%
Revenue Next 2Y51.01%
Revenue Next 3Y51.09%
Revenue Next 5Y46.04%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
SNDX Yearly Revenue VS EstimatesSNDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
SNDX Yearly EPS VS EstimatesSNDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SNDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SNDX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNDX Price Earnings VS Forward Price EarningsSNDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNDX Per share dataSNDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

SNDX's earnings are expected to grow with 16.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.05%
EPS Next 3Y16.07%

More info and screens

0

5. Dividend

5.1 Amount

SNDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SYNDAX PHARMACEUTICALS INC

NASDAQ:SNDX (5/23/2025, 1:54:56 PM)

10.08

-0.73 (-6.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/amc
Earnings (Next)07-30 2025-07-30
Inst Owners117.23%
Inst Owner Change28.48%
Ins Owners1.25%
Ins Owner Change11.2%
Market Cap867.28M
Analysts85.26
Price Target35.51 (252.28%)
Short Float %25.49%
Short Ratio10.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-171.41%
Min EPS beat(2)-370.62%
Max EPS beat(2)27.8%
EPS beat(4)3
Avg EPS beat(4)-78.74%
Min EPS beat(4)-370.62%
Max EPS beat(4)27.8%
EPS beat(8)7
Avg EPS beat(8)-34.3%
EPS beat(12)11
Avg EPS beat(12)-20.85%
EPS beat(16)14
Avg EPS beat(16)16.28%
Revenue beat(2)1
Avg Revenue beat(2)-27.55%
Min Revenue beat(2)-91.24%
Max Revenue beat(2)36.14%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.49%
PT rev (3m)-3.67%
EPS NQ rev (1m)3.11%
EPS NQ rev (3m)4.98%
EPS NY rev (1m)4.79%
EPS NY rev (3m)5.81%
Revenue NQ rev (1m)13.22%
Revenue NQ rev (3m)19.32%
Revenue NY rev (1m)12.21%
Revenue NY rev (3m)8.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.84
P/FCF N/A
P/OCF N/A
P/B 4.03
P/tB 4.03
EV/EBITDA N/A
EPS(TTM)-3.86
EYN/A
EPS(NY)-2.69
Fwd EYN/A
FCF(TTM)-3.33
FCFYN/A
OCF(TTM)-3.33
OCFYN/A
SpS0.51
BVpS2.5
TBVpS2.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.69%
ROE -154.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 52.27%
FCFM N/A
ROA(3y)-36.06%
ROA(5y)-25.66%
ROE(3y)-60.12%
ROE(5y)-40.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 1.54
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.8
Quick Ratio 5.75
Altman-Z -2.39
F-Score3
WACC9.78%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-15.29%
EPS Next Y-0.52%
EPS Next 2Y13.05%
EPS Next 3Y16.07%
EPS Next 5Y15.95%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-44.66%
Revenue growth 5Y73.64%
Sales Q2Q%N/A
Revenue Next Year4.29%
Revenue Next 2Y51.01%
Revenue Next 3Y51.09%
Revenue Next 5Y46.04%
EBIT growth 1Y-30.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.67%
EBIT Next 3Y17.81%
EBIT Next 5YN/A
FCF growth 1Y-118.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-118.75%
OCF growth 3YN/A
OCF growth 5YN/A